• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Fredrick J Stanley

    6/5/25 2:34:53 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FREDRICK J STANLEY

    (Last) (First) (Middle)
    1410 LAKESIDE PARKWAY
    SUITE 200

    (Street)
    FLOWER MOUND TX 75028

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MANNATECH INC [ MTEX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock Par Value $0.0001 Per Share 356,975(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Right to Purchase Common Stock $10.36 06/04/2025 A 5,000 (2) 06/04/2035 Common Stock, par value $0.0001 per share 5,000 $0 20,000 D
    Explanation of Responses:
    1. The number of shares owned by Fredrick J Stanley includes 231,975 shares of our common stock directly held by Fredrick J Stanley and 125,000 shares of our common stock held through JSF Resources LTD Partnership. JSF Resources LTD is a limited partnership that is owned by FSJ Secure Trust, of which Fredrick J Stanley is the sole beneficiary.
    2. One-third of the stock options vest on the date of grant, another one-third of the stock options vest on the first anniversary of the date of grant, and the remaining one-third of the stock options vest on the second anniversary of the date of grant.
    Remarks:
    Yasir Haider, Controller, by Power of Attorney 06/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fredrick J Stanley

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:53 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by President and CEO Fredrick Landen Granvel

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:36 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by General Counsel Barta Erin Kemmler

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:21 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      6/4/25 5:06:08 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

      6/5/25 2:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

      6/5/25 2:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care